Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | CCR5 | P51681 | 6/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13738460 | 0.89 | HRH3 (0.43) | SMN1; SMN2OPRM1SIGMAR1CCR5HRH3 | |
| SCHEMBL13738461 | 0.89 | HRH3 (0.43) | SMN1; SMN2OPRM1SIGMAR1CCR5HRH3 | |
| SCHEMBL15668110 | 0.89 | HRH3 (0.43) | SMN1; SMN2OPRM1SIGMAR1CCR5HRH3 | |
| SCHEMBL12617041 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2OPRM1SIGMAR1CCR5DRD2 | |
| SCHEMBL25479794 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2OPRM1SIGMAR1CCR5DRD2 | |
| SCHEMBL18346732 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2OPRM1SIGMAR1CCR5DRD2 | |
| SCHEMBL20462329 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2OPRM1SIGMAR1CCR5DRD2 | |
| SCHEMBL23696551 | 0.80 | CCR5 (0.47) | SMN1; SMN2SIGMAR1CCR5DRD2HTR2A | |
| SCHEMBL4270991 | 0.80 | CCR5 (0.44) | CCR5 | |
| SCHEMBL3466035 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2OPRM1SIGMAR1CCR5HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| EP-2513110-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073263-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| CN-101443325-A | 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163467-A1 | New compounds | CCNA1, MKI67, CCNT1 | SMN1; SMN2 254/4885OPRM1 457/4885SIGMAR1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.